(2S)-[(2S)-aminopropionylamino]-3-{trans-(2S)-[((3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl)amino]cyclopropyl}propionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-[(2S)-aminopropionylamino]-3-{trans-(2S)-[((3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl)amino]cyclopropyl}propionic acid
• 英文别名: (+)-belactosin A；belactosin A；(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-[(1R,2S)-2-[[(2R,3S)-3-[(2S)-butan-2-yl]-4-oxooxetane-2-carbonyl]amino]cyclopropyl]propanoic acid
• 化学式: C₁₇H₂₇N₃O₆
• 分子量: 369.418
• InChiKey: ZSYIAUXMQLVKIL-SMFJDMQNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  148
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  L-异亮氨酸 在 palladium on activated charcoal 氢氧化钾 、 lithium hydroxide 、 正丁基锂 、 甲酸 、 草酰氯 、 氢气 、 双氧水 、 sodium hexamethyldisilazane 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 、 lithium hexamethyldisilazane 、 hydroxylamine-O-sulfonic acid 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 为溶剂， 反应 23.0h， 生成 (2S)-[(2S)-aminopropionylamino]-3-{trans-(2S)-[((3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl)amino]cyclopropyl}propionic acid
  参考文献：
  名称：

  Total synthesis of (+)-belactosin A

  摘要：

  本研究首次报道了抗肿瘤抗生素贝拉糖苷 A 的简明全合成，其中涉及 β-内酯羧酸 3 与 N-丙氨环丙基丙氨酸 11 的偶联。

  DOI：

  10.1039/b316142k

文献信息

• Three-dimensional structure-activity relationship study of belactosin A and its stereo- and regioisomers: development of potent proteasome inhibitors by a stereochemical diversity-oriented strategy
  作者：Keisuke Yoshida、Kazuya Yamaguchi、Akira Mizuno、Yuka Unno、Akira Asai、Takayuki Sone、Hideyoshi Yokosawa、Akira Matsuda、Mitsuhiro Arisawa、Satoshi Shuto

  DOI：10.1039/b900384c

  日期：——

  The development of potent proteasome inhibitors based on the stereochemical diversity-oriented strategy using a conformationally rigid cyclopropane structure was investigated. Thus, a series of stereo- and regioisomeric analogs of belactosin A (2), a cyclopropane amino acid (methanoamino acid)-containing tripeptidic proteasome inhibitor, were designed, in which the central cyclopropane amino acid part

  研究了基于构象刚性环丙烷结构的基于立体化学多样性导向策略的有效蛋白酶体抑制剂的开发。因此，设计了一系列的Belactosin A（2）立体异构体和区域异构体，这是一种含有环丙烷氨基酸（甲氨基氨基酸）的三肽蛋白酶体抑制剂，其中中央的环丙烷氨基酸部分被相应的立体异构体或区域异构体。使用一系列立体异构体的环丙烷氨基酸等效物，具有顺/反，D / L和syn / anti我们先前开发的立体化学多样性作为关键单元，已成功合成了目标化合物。生物学评价表明，如所预期，化合物活性改取决于中心环丙烷氨基酸部分的立体化学：在反式/ L-顺式异构体7和所述顺式/ L-抗-异构体9分别超过两倍强效天然Belactosin A（反式/ L-反异构体）。此外，三肽化合物13，非天然的顺式/ L-抗异构体9的合成前体被鉴定为高效蛋白酶体抑制剂。该化合物的效力是贝洛斯托因A的20倍，甚至比众所周知的抑制剂乳腺抑肽（4）更有
• Novel method for the asymmetric synthesis of beta-lactone compounds
  申请人：Smith W. Jeffrey

  公开号：US20060258620A1

  公开（公告）日：2006-11-16

  The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

  本发明涉及通过向患者施用有效量的β-内酰胺来治疗患者身上的癌症的方法。本发明还涉及通过向患者施用脂肪酸合成酶抑制剂的有效量来抑制患者身上的血管生成的方法。这些方法可以用于治疗各种癌症和其他疾病和病况。本发明还涉及识别β-内酰胺和其他化合物的方法，这些化合物可以用于本发明中用于治疗肿瘤、抑制血管生成以及治疗涉及病理性血管生成的疾病和病况的方法。本发明还涉及合成β-内酰胺的方法和新型β-内酰胺化合物的特点。
• NOVEL METHOD FOR THE ASYMMETRIC SYNTHESIS OF BETA-LACTONE COMPOUNDS
  申请人：Smith Jeffrey W.

  公开号：US20100173982A1

  公开（公告）日：2010-07-08

  The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

  本发明涉及通过向受试者施用有效量的β-内酰胺来治疗癌症的方法。本发明还涉及通过向受试者施用脂肪酸合成酶抑制剂的有效量来抑制血管生成的方法。这些方法可用于治疗各种癌症和其他疾病和病况。本发明还涉及识别β-内酰胺和其他化合物的方法，这些化合物可用于本发明的治疗肿瘤、抑制血管生成以及涉及病理性血管生成的疾病和病况的方法。本发明还涉及β-内酰胺的合成方法和新型β-内酰胺化合物。
• Enantioselective Total Syntheses of Belactosin A, Belactosin C, and Its Homoanalogue
  作者：Oleg V. Larionov、Armin de Meijere

  DOI：10.1021/ol049409+

  日期：2004.6.1

  Enantioselective total syntheses of belactosin A, belactosin C, and its homoanalogue have been accomplished in high overall yields (32% for belactosin A from the amino acid 10, and 35 and 36% for belactosin C and its homoanalogue, respectively). This concise approach comprises a novel sequential acylation/beta-lactonization reaction and allows a facile alteration of the substituents, thus providing a flexible route to a new family of highly active belactosin-based proteasome inhibitors.
• Synthesis of 2,3- and 3,4-Methanoamino Acid Equivalents with Stereochemical Diversity and Their Conversion into the Tripeptide Proteasome Inhibitor Belactosin A and Its Highly Potent <i>Cis</i>-Cyclopropane Stereoisomer
  作者：Keisuke Yoshida、Kazuya Yamaguchi、Takayuki Sone、Yuka Unno、Akira Asai、Hideyoshi Yokosawa、Akira Matsuda、Mitsuhiro Arisawa、Satoshi Shuto

  DOI：10.1021/ol8013304

  日期：2008.8.21

  A series of chiral 2,3- and 3,4-methanoamino acid equivalents of stereochernical diversity were designed and synthesized from our chiral cyclopropane units, using a diastereoselective Grignard addition with (R)- or (S)-t-butanesulfinyl imines as the key step. These equivalents were converted into the proteasome inhibitor belactosin A and its cis-cyclopropane stereoisomer. The unnatural cis-isomer was shown to be more than twice as potent as belactosin A as a proteasome inhibitor.